.jpeg)
2026-03-18 06:00:53
Latest systematic review study finds that use of tyrosine kinase inhibitors and Janus kinase inhibitors may be associated with increased keratinocyte carcinoma risk, providing important reference for tumor drug therapy safety assessment.
2026-03-18 05:49:30
CLISGen is an innovative database platform integrating SNP genotype information from cancer cell lines, containing genetic data from over 1000 cancer cell lines, helping researchers efficiently select cell models with specific genetic variations and breaking through bottlenecks in tumor functional genomics research.
2026-03-18 05:32:12
Apremilast is an oral small-molecule PDE4 inhibitor used to treat psoriasis, psoriatic arthritis and Behcet's disease. This article explains its mechanism, efficacy and safety.
2026-03-17 07:23:12
Records the complete treatment journey of an ALK-positive non-small cell lung cancer patient using Brigatinib, covering initial medication reactions, side effect management, efficacy evaluation, and lifestyle adjustments, providing real reference for similar patients.
2026-03-17 07:09:35
Brigatinib is a second-generation ALK inhibitor designed for ALK-positive non-small cell lung cancer patients. This article details drug mechanism, indications, side effect management, and latest clinical advances to support scientific medication use.
2026-03-17 06:58:36
MDS targeted drugs are not chemotherapy; they are precision treatments targeting specific molecular markers. This article details the mechanistic differences, the critical role of genetic testing, side effect comparisons, and personalized strategies for children, the elderly, and patients with comorbidities.
2026-03-17 02:50:08
Repotrectinib is a ROS1/NTRK targeted anticancer drug developed by Bristol-Myers Squibb, approved in China in 2024. This article details drug origin, pricing, supply channels, and eligible patient populations for comprehensive medication reference.
2026-03-16 07:12:44
Ceritinib is a common oral targeted medication for non-small cell lung cancer. This article details drug storage temperature, environmental requirements, expiration date identification, and abnormal condition handling for safe medication use.
2026-03-16 06:56:17
Selumetinib is an oral MEK inhibitor for treating Type 1 Neurofibromatosis (NF1). This article details drug mechanism, SPRINT clinical data, indications, dosage guidelines, and safety management.
2026-03-13 07:08:13
Enasidenib is the first approved oral IDH2 inhibitor, brand name Idhifa, designed for patients with relapsed or refractory acute myeloid leukemia carrying IDH2 mutations. This article details mechanism of action, indications, dosage and adverse reaction management.
2026-03-13 05:38:15
Anagrelide is an oral platelet production inhibitor for treating essential thrombocythemia. This article covers indications, recommended dosage, administration methods, efficacy monitoring and common side effects for safe medication use.
2026-03-12 07:35:33
RAS mutations account for approximately 30% of malignancies, but resistance limits clinical benefits. New research reveals sustained mTORC1 activity as a non-genetic driver of RAS inhibitor resistance. Farnesyltransferase inhibitor Dalifarnib (KO-2806) blocks mTORC1 activation via RHEB, achieving rapid durable tumor regression when combined with RAS inhibitors.
